>Mercado de tumores neuroendócrinos da Ásia-Pacífico, por classificação (rede funcional e rede não funcional), local (pulmão, pâncreas, trato gastrointestinal (GI), grau (grau 1 {tumor de baixo grau}, grau 2 {tumor de grau intermédio } , grau 3 {tumor de grau elevado}), tipo (diagnóstico e tratamento), via de administração (oral e parentérica), modo de compra (prescrição e balcão (OTC)), utilizador final (hospitais, clínicas especializadas, radiação Centros , Cuidados de Saúde Domiciliários e Outros), Canal de Distribuição (Concurso Directo, Farmácias Hospitalares, Farmácias de Retalho, Farmácias Online e Outros), País (China, Japão, Índia, Austrália, Coreia do Sul, Singapura, Tailândia, Malásia, Indonésia , Filipinas, Vietname , resto da Ásia-Pacífico) Tendências e previsões da indústria para 2028
Análise de mercado e insights : Mercado de tumores neuroendócrinos da Ásia-Pacífico
Espera-se que o mercado de tumores neuroendócrinos ganhe crescimento de mercado no período de previsão de 2021 a 2028. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 11,5% no período de previsão de 2021 a 2028 e deverá atingir os 929,49 milhões de dólares até 2028. As iniciativas estratégicas dos participantes do mercado e o advento de programas de vacinação em massa para tumores neuroendócrinos serão provavelmente os principais impulsionadores que impulsionaram a procura do mercado no período de previsão.
O início do tumor ocorre quando o ADN das células saudáveis é danificado, o que faz com que as células se alterem e cresçam de forma descontrolada, formando assim uma massa agregada de células. Um tumor pode ser canceroso e benigno. Um tumor cancerígeno maligno cresce e espalha-se para outras partes do corpo se não for detetado precocemente e tratado. Um tumor benigno pode crescer, mas não se espalhará. Um tumor benigno pode geralmente ser removido com o uso de cirurgia minimamente invasiva sem causar muitos danos. Um tumor neuroendócrino (TNE) começa nas células especializadas do sistema neuroendócrino do corpo. Estas células têm características comuns tanto das células endócrinas produtoras de hormonas como das células nervosas. Encontram-se em todos os órgãos do corpo e são responsáveis por controlar muitas das funções do organismo. Todos os TNE são considerados tumores malignos. A maioria das NET demora muitos anos a desenvolver-se e a crescer lentamente.
No entanto, os fatores como efeitos secundários associados aos tratamentos, necessidades não satisfeitas e acesso a recursos médicos em diversas regiões, elevado custo do diagnóstico estão a dificultar o crescimento do mercado dos tumores neuroendócrinos. Por outro lado, os próximos tratamentos direcionados e o aumento das parcerias e colaborações entre os players do mercado atuam como uma oportunidade para o crescimento do mercado dos tumores neuroendócrinos. A falta de políticas de comparticipação e as rigorosas regulamentações governamentais para o desenvolvimento de medicamentos para os tumores neuroendócrinos são os desafios enfrentados no mercado dos tumores neuroendócrinos.
O relatório do mercado de tumores neuroendócrinos fornece detalhes de quota de mercado, novos desenvolvimentos e análise de pipeline de produtos, impacto dos participantes do mercado doméstico e localizado, analisa as oportunidades em termos de bolsas de receitas emergentes, alterações nas regulamentações de mercado, aprovações de produtos, decisões estratégicas, lançamentos de produtos, expansões geográficas e inovações tecnológicas no mercado. Para compreender a análise e o cenário do mercado contacte-nos para um Analyst Brief, a nossa equipa irá ajudá-lo a criar uma solução de impacto na receita para atingir o objetivo desejado.
Âmbito e dimensão do mercado de tumores neuroendócrinos
O mercado dos tumores neuroendócrinos está segmentado com base na classificação, local, grau, tipo, via de administração, utilizador final e canal de distribuição. O crescimento entre segmentos ajuda-o a analisar os nichos de crescimento e as estratégias para abordar o mercado e determinar as suas principais áreas de aplicação e a diferença nos seus mercados-alvo.
- Com base na classificação , o mercado dos tumores neuroendócrinos está segmentado em rede funcional e rede não funcional. Em 2021, o segmento das redes não funcionais está a dominar o mercado dos tumores neuroendócrinos devido à facilidade de identificação e diagnóstico e à utilização de novos métodos de diagnóstico para remover a rede não funcional.
- Com base no local, o mercado dos tumores neuroendócrinos está segmentado em pulmão , pâncreas e trato gastrointestinal (GI). Em 2021, o segmento do trato gastrointestinal (GI) está a dominar o mercado dos tumores neuroendócrinos devido ao aumento da prevalência do cancro gástrico e prevê-se que a presença de um forte pipeline de produtos domine o mercado.
- Com base no grau, o mercado dos tumores neuroendócrinos está segmentado em grau 1 (tumor de baixo grau), grau 2 (tumor de grau intermédio) e grau 3 (tumor de alto grau). Em 2021, o segmento de grau 2 (tumor de grau intermédio) está a dominar o mercado dos tumores neuroendócrinos, uma vez que pode ser facilmente curado por tratamentos terapêuticos e prevê-se que o aumento dos casos de grau 2 (tumor de grau intermédio) dominar o mercado.
- Com base no tipo, o mercado dos tumores neuroendócrinos está segmentado em diagnóstico e tratamento. Em 2021, prevê-se que o segmento de diagnóstico domine o mercado dos tumores neuroendócrinos devido ao aumento da incidência de tumor de cancro do pâncreas e ao aumento da adoção do diagnóstico automatizado de ponto de atendimento no mercado.
- Com base na via de administração, o mercado dos tumores neuroendócrinos está segmentado em oral e parentérica. Em 2021, prevê-se que o segmento oral domine o mercado dos tumores neuroendócrinos devido à disponibilidade de medicamentos na forma oral, maior adesão dos doentes e facilidade de absorção.
- On the basis of end user, the neuroendocrine tumors market is segmented into hospitals, specialty clinics, radiation centers, home healthcare and others. In 2021, hospitals segment is expected to dominate the neuroendocrine tumors market due to the availability of diagnostics machines to detect neuroendocrine tumor with the availability of healthcare policies.
- On the basis of distribution channel, the neuroendocrine tumors market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others. In 2021, direct tender segment is expected to dominate the neuroendocrine tumors market due to rise of suppliers in the market.
Neuroendocrine Tumors Market Country Level Analysis
The neuroendocrine tumors market is analysed and market size information is provided classification, site, grade, type, route of administration, end user and distribution channel as referenced above.
The countries covered in the neuroendocrine tumors market report are China, Japan, India, Australia, South Korea, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, rest of Asia-Pacific.
Asia-Pacific is expected to grow with the highest CAGR in the forecast period. China is expected to dominate in the market as the demand for neuroendocrine tumors product is increasing very rapidly with the urbanization and laboratory automation.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Rise in Government Initiatives and the Rising Collaborations by Market Players are creating new Opportunities in the Neuroendocrine Tumors Market
Neuroendocrine tumors market also provides you with detailed market analysis for every country growth in particular industry with neuroendocrine tumors sales, impact of advancement in the neuroendocrine tumors and changes in regulatory scenarios with their support for the neuroendocrine tumors market. The data is available for historic period 2010 to 2019.
Competitive Landscape and Neuroendocrine Tumors Market Share Analysis
O panorama competitivo do mercado de tumores neuroendócrinos fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos, pipelines de testes de produtos, aprovações de produtos, patentes, largura e amplitude do produto, domínio de aplicação, curva de segurança da tecnologia. Os dados acima fornecidos estão apenas relacionados com o foco da empresa relacionado com o mercado dos tumores neuroendócrinos.
As principais empresas no mercado dos tumores neuroendócrinos são a Novartis AG, Ipsen Pharma, Viatris Inc., Callisto Pharmaceuticals, Eli Lilly and Company, Bristol-Myers Squibb Company, Pfizer Inc., GlaxoSmithKline plc, Thermo Fisher Scientific Inc., Hutchison China MediTech Limited , F. Hoffmann-La Roche Ltd, Bionano Genomics, Teva Pharmaceutical Industries Ltd., Merck Sharp & Dohme Corp., uma subsidiária da Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Illumina, Inc., e LUPINE entre outros atores globais ou nacionais. Os analistas DBMR compreendem os pontos fortes competitivos e fornecem análises competitivas para cada concorrente em separado.
Muitos lançamentos e acordos de produtos são também iniciados pelas empresas de todo o mundo que também estão a acelerar o mercado dos tumores neuroendócrinos.
Por exemplo,
- Em janeiro de 2018 , a Novartis AG proclamou que a Advanced Accelerator Applications, uma subsidiária da Novartis AG, recebeu a aprovação da FDA para o seu novo pedido de medicamento Lutathera (lutécio Lu 177 dotatate*) para o tratamento de tumores neuroendócrinos gastroenteropancreáticos positivos para recetor de somatostatina (GEP-NETs). incluindo tumores neuroendócrinos do intestino anterior, médio e posterior em adultos. A aprovação da FDA recebida pela empresa resultou no aumento dos ensaios clínicos, melhorou o portefólio de produtos oncológicos em neurologia e proporcionaria um crescimento positivo no mercado.
A colaboração, as joint ventures e outras estratégias do player de mercado estão a potenciar o mercado da empresa no mercado dos tumores neuroendócrinos, o que também proporciona o benefício para a organização melhorar a sua oferta de tratamento.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 CLASSIFICATION LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 PIPELINE ANALYSIS
6 PRICING ANALYSIS
7 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: REGULATIONS
7.1 REGULATORY PROCEDURE IN THE U.S.
7.2 REGULATORY PROCEDURE IN CANADA
7.3 REGULATORY PROCEDURE IN EUROPE
7.4 REGULATORY PROCEDURE IN CHINA
7.5 REGULATORY PROCEDURE IN MIDDLE EAST AND AFRICA
8 COMPARITIVE ANALYSIS BETWEEN MONOCLONAL AND POLYCLONAL ANTIBODY
8.1 MONOCLONAL ANTIBODY
8.2 POLYCLONAL ANTIBODY
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 INCREASED INCIDENCE OF NEUROENDOCRINE TUMOR CASES
9.1.2 TECHNOLOGICAL ADVANCEMENT FOR THE DETECTION OF NEUROENDOCRINE TUMORS
9.1.3 GROWTH IN THE NUMBER OF PRIVATE DIAGNOSTIC CENTERS AND TREATMENT PROVIDERS
9.1.4 PRESENCE OF TARGETED TREATMENT OPTIONS
9.1.5 FAVORABLE REIMBURSEMENT POLICIES
9.2 RESTRAINTS
9.2.1 HIGH CAPITAL INVESTMENTS & LOW BENEFIT-COST RATIO FOR BIOMARKERS AND ORPHAN DRUGS
9.2.2 LACK OF AWARENESS AMONG THE POPULATION
9.2.3 UNMET NEEDS AND ACCESS TO MEDICAL RESOURCES IN SEVERAL REGIONS
9.2.4 HIGH COST OF DIAGNOSIS
9.3 OPPORTUNITIES
9.3.1 INCREASED GOVERNMENT INITIATIVES
9.3.2 EMERGING THERAPIES & DEVELOPMENT IN TREATMENT
9.3.3 RISING COLLABORATIONS AMONG THE MARKET PLAYERS
9.4 CHALLENGES
9.4.1 SIDE EFFECTS ASSOCIATED WITH TREATMENTS
9.4.2 STRINGENT GOVERNMENT REGULATIONS FOR THE DEVELOPMENT OF NEUROENDOCRINE TUMOR DRUGS
10 IMPACT OF COVID 19 ON ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET
10.1 PRICE IMPACT
10.2 IMPACT OF DEMAND
10.3 IMPACT ON SUPPLY CHAIN:
10.4 STRATEGIC DECISIONS:
10.5 CONCLUSION:
11 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION
11.1 OVERVIEW
11.2 NON-FUNCTIONAL NET
11.3 FUNTIONAL NET
12 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY SITE
12.1 OVERVIEW
12.2 GASTROINTESTINAL TRACT (GI)
12.3 LUNGS
12.4 PANCREAS
13 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY GRADE
13.1 OVERVIEW
13.2 GRADE 2 (INTERMEDIATE-GRADE TUMOR)
13.3 GRADE 3 (HIGH-GRADE TUMOR)
13.4 GRADE 1( LOW-GRADE TUMOR)
14 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY TYPE
14.1 OVERVIEW
14.2 DIAGNOSIS
14.2.1 BLOOD TEST
14.2.2 IMAGING TEST
14.2.2.1 CTSCAN
14.2.2.2 MRI
14.2.2.3 OTHERS
14.2.3 BIOPSY
14.2.4 URINE TEST
14.2.5 OTHERS
14.3 TREATMENT
14.3.1 SOMATOSTATIN ANALOGS
14.3.1.1 OCTREOTIDE
14.3.1.2 LANREOTIDE
14.3.2 TARGETED THERAPY
14.3.2.1 EVEROLIMUS
14.3.2.2 SUNITINIB
14.3.2.3 OTHERS
14.3.3 RADIATION THERAPY
14.3.3.1 EXTERNAL-BEAM RADIATION
14.3.3.2 INTERNAL-BEAM RADIATION
14.3.4 SURGERY
14.3.4.1 CHOLECYSTECTOMY
14.3.4.2 OTHERS
14.3.5 LIVER-DIRECTED TREATMENT
14.3.5.1 RADIO FREQUENCY ABLATION (RFA)
14.3.5.2 HEPATIC ARTERY EMBOLIZATION
14.3.5.3 RADIOEMBOLIZATION
14.3.6 PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT)/ LUTATHERA
15 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION
15.1 OVERVIEW
15.2 ORAL
15.2.1 TABLETS
15.2.2 PILLS
15.2.3 OTHERS
15.3 PARENTERAL
15.3.1 SUBCUTANEOUS
15.3.2 INTRAMUSCULAR
15.3.3 OTHERS
16 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY END USER
16.1 OVERVIEW
16.2 HOSPITALS
16.3 SPECIALITY CLINICS
16.4 RADIATION CENTERS
16.5 HOME HEALTHCARE
16.6 OTHERS
17 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL
17.1 OVERVIEW
17.2 DIRECT TENDER
17.3 HOSPITAL PHARMACY
17.4 RETAIL SALES
17.5 ONLINE PHARMACY
17.6 OTHERS
18 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY GEOGRAPHY
18.1 ASIA PACIFIC
18.1.1 CHINA
18.1.2 JAPAN
18.1.3 INDIA
18.1.4 AUSTRALIA
18.1.5 MALAYSIA
18.1.6 INDONESIA
18.1.7 SOUTH KOREA
18.1.8 SINGAPORE
18.1.9 PHILIPPINESS
18.1.10 THAILAND
18.1.11 VIETNAM
18.1.12 REST OF ASIA-PACIFIC
19 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
20 SWOT
21 COMPANY PROFILES
21.1 F. HOFFMANN-LA ROCHE LTD
21.1.1 COMPANY SNAPSHOT
21.1.2 REVENUE ANALYSIS
21.1.3 COMPANY SHARE ANALYSIS
21.1.4 PRODUCT PORTFOLIO
21.1.5 RECENT DEVELOPMENTS
21.2 BRISTOL-MYERS SQUIBB COMPANY
21.2.1 COMPANY SNAPSHOT
21.2.2 REVENUE ANALYSIS
21.2.3 COMPANY SHARE ANALYSIS
21.2.4 PRODUCT PORTFOLIO
21.2.5 RECENT DEVELOPMENTS
21.3 VIATRIS INC.
21.3.1 COMPANY SNAPSHOT
21.3.2 COMPANY SHARE ANALYSIS
21.3.3 PRODUCT PORTFOLIO
21.3.4 RECENT DEVELOPMENTS
21.4 THERMO FISHER SCIENTIFIC INC.
21.4.1 COMPANY SNAPSHOT
21.4.2 REVENUE ANALYSIS
21.4.3 COMPANY SHARE ANALYSIS
21.4.4 PRODUCT PORTFOLIO
21.4.5 RECENT DEVELOPMENTS
21.5 NOVARTIS AG
21.5.1 COMPANY SNAPSHOT
21.5.2 REVENUE ANALYSIS
21.5.3 COMPANY SHARE ANALYSIS
21.5.4 PRODUCT PORTFOLIO
21.5.5 RECENT DEVELOPMENTS
21.6 REGENERON PHARMACEUTICALS, INC.
21.6.1 COMPANY SNAPSHOT
21.6.2 REVENUE ANALYSIS
21.6.3 PRODUCT PORTFOLIO
21.6.4 RECENT DEVELOPMENTS
21.7 ADVANCED ACCELERATOR APPLICATIONS (A SUBSIDIARY OF NOVARTIS AG)
21.7.1 COMPANY SNAPSHOT
21.7.2 REVENUE ANALYSIS
21.7.3 PRODUCT PORTFOLIO
21.7.4 RECENT DEVELOPMENTS
21.8 BIONANO GENOMICS
21.8.1 COMPANY SNAPSHOT
21.8.2 PRODUCT PORTFOLIO
21.8.3 RECENT DEVELOPMENTS
21.9 BIOSYNTHEMA INC.
21.9.1 COMPANY SNAPSHOT
21.9.2 PRODUCT PORTFOLIO
21.9.3 RECENT DEVELOPMENTS
21.1 CALLISTOPHARMA
21.10.1 COMPANY SNAPSHOT
21.10.2 PRODUCT PORTFOLIO
21.10.3 RECENT DEVELOPMENTS
21.11 ELI LILLY AND COMPANY
21.11.1 COMPANY SNAPSHOT
21.11.2 REVENUE ANALYSIS
21.11.3 PRODUCT PORTFOLIO
21.11.4 RECENT DEVELOPMENTS
21.12 EXACT SCIENCES CORPORATION
21.12.1 COMPANY SNAPSHOT
21.12.2 REVENUE ANALYSIS
21.12.3 PRODUCT PORTFOLIO
21.12.4 RECENT DEVELOPMENTS
21.13 GLAXOSMITHKLINE PLC
21.13.1 COMPANY SNAPSHOT
21.13.2 REVENUE ANALYSIS
21.13.3 PRODUCT PORTFOLIO
21.13.4 RECENT DEVELOPMENTS
21.14 HUTCHISON CHINA MEDITECH LIMITED
21.14.1 COMPANY SNAPSHOT
21.14.2 REVENUE ANALYSIS
21.14.3 PRODUCT PORTFOLIO
21.14.4 RECENT DEVELOPMENTS
21.15 IPSEN PHARMA
21.15.1 COMPANY SNAPSHOT
21.15.2 REVENUE ANALYSIS
21.15.3 PRODUCT PORTFOLIO
21.15.4 RECENT DEVELOPMENTS
21.16 ILLUMINA, INC.
21.16.1 COMPANY SNAPSHOT
21.16.2 REVENUE ANALYSIS
21.16.3 PRODUCT PORTFOLIO
21.16.4 RECENT DEVELOPMENTS
21.17 LUPIN
21.17.1 COMPANY SNAPSHOT
21.17.2 REVENUE ANALYSIS
21.17.3 PRODUCT PORTFOLIO
21.17.4 RECENT DEVELOPMENTS
21.18 MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.
21.18.1 COMPANY SNAPSHOT
21.18.2 REVENUE ANALYSIS
21.18.3 PRODUCT PORTFOLIO
21.18.4 RECENT DEVELOPMENTS
21.19 PFIZER INC.
21.19.1 COMPANY SNAPSHOT
21.19.2 REVENUE ANALYSIS
21.19.3 PRODUCT PORTFOLIO
21.19.4 RECENT DEVELOPMENTS
21.2 SUN PHARMACEUTICAL INDUSTRIES LTD.
21.20.1 COMPANY SNAPSHOT
21.20.2 REVENUE ANALYSIS
21.20.3 PRODUCT PORTFOLIO
21.20.4 RECENT DEVELOPMENTS
21.21 TEVA PHARMACEUTICAL INDUSTRIES LTD.
21.21.1 COMPANY SNAPSHOT
21.21.2 REVENUE ANALYSIS
21.21.3 PRODUCT PORTFOLIO
21.21.4 RECENT DEVELOPMENTS
22 QUESTIONNAIRE
23 RELATED REPORTS
Lista de Tabela
TABLE 1 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, PIPELINE ANALYSIS
TABLE 2 SALES DATA OF ONCOLOGY MARKET FOR 2019/2020
TABLE 3 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION 2019-2028(USD MILLION)
TABLE 4 ASIA-PACIFIC NON-FUNCTIONAL NET IN NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION 2019-2027 (USD MILLION)
TABLE 5 ASIA-PACIFIC FUNCTIONAL NET IN NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION 2019-2027 (USD MILLION)
TABLE 6 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY SITE 2019-2028 (USD MILLION)
TABLE 7 ASIA-PACIFIC GASTROINTESTINAL TRACT (GI) IN NEUROENDOCRINE TUMORS MARKET, BY SITE 2019-2028 (USD MILLION)
TABLE 8 ASIA-PACIFIC LUNGS IN NEUROENDOCRINE TUMORS MARKET, BY SITE 2019-2028 (USD MILLION)
TABLE 9 ASIA-PACIFIC PANCREAS NEUROENDOCRINE TUMORS MARKET, BY SITE 2019-2028 (USD MILLION)
TABLE 10 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY GRADE 2019-2028 (USD MILLION)
TABLE 11 ASIA-PACIFIC GRADE 2 (INTERMEDIATE-GRADE TUMOR) IN NEUROENDOCRINE TUMORS MARKET, BY GRADE 2019-2028 (USD MILLION)
TABLE 12 ASIA-PACIFIC GRADE 3 (HIGH-GRADE TUMOR) IN NEUROENDOCRINE TUMORS MARKET, BY GRADE 2019-2028 (USD MILLION)
TABLE 13 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY GRADE 2019-2028 (USD MILLION)
TABLE 14 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 15 ASIA-PACIFIC DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 16 ASIA-PACIFIC DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 17 ASIA-PACIFIC IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 18 ASIA-PACIFIC TREATMENT NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 19 ASIA-PACIFIC TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 20 ASIA-PACIFIC SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 21 ASIA-PACIFIC TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 22 ASIA-PACIFIC RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 23 ASIA-PACIFIC SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 24 ASIA-PACIFIC LIVER-DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 25 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 26 ASIA-PACIFIC ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 27 ASIA-PACIFIC ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 28 ASIA-PACIFIC PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 29 ASIA-PACIFIC PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 30 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 31 ASIA-PACIFIC HOSPITALS IN NEUROENDOCRINE TUMORS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 32 ASIA-PACIFIC SPECIALITY CLINICS IN NEUROENDOCRINE TUMORS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 33 ASIA-PACIFIC RADIATION CENTERS IN NEUROENDOCRINE TUMORS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 34 ASIA-PACIFIC OTHERS IN RADIOTHERAPY MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 35 ASIA-PACIFIC OTHERS IN NEUROENDOCRINE TUMORS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 36 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 37 ASIA-PACIFIC DIRECT TENDER IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 38 ASIA-PACIFIC HOSPITAL PHARMACY IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 39 ASIA-PACIFIC RETAIL SALES IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 40 ASIA-PACIFIC ONLINE PHARMACY IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 41 ASIA-PACIFIC OTHERS IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 42 ASIA PACIFIC NEUROENDOCRINE TUMORS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 43 ASIA PACIFICNEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 44 ASIA PACIFICNEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 45 ASIA PACIFICNEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 46 ASIA PACIFICNEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 47 ASIA PACIFICDIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 48 ASIA PACIFICIMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 49 ASIA PACIFICTREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 50 ASIA PACIFICSOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 51 ASIA PACIFICTARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 52 ASIA PACIFICRADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 53 ASIA PACIFICSURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 54 ASIA PACIFICLIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 55 ASIA PACIFICNEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 56 ASIA PACIFICORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 57 ASIA PACIFICPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 58 ASIA PACIFICNEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 59 ASIA PACIFIC NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 60 CHINANEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 61 CHINANEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 62 CHINANEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 63 CHINANEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 64 CHINADIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 65 CHINAIMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 66 CHINATREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 67 CHINASOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 68 CHINATARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 69 CHINARADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 70 CHINASURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 71 CHINALIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 72 CHINANEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 73 CHINAORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 74 CHINAPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 75 CHINANEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 76 CHINA NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 77 JAPANNEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 78 JAPANNEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 79 JAPANNEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 80 JAPANNEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 81 JAPANDIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 82 JAPANIMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 83 JAPANTREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 84 JAPANSOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 85 JAPANTARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 86 JAPANRADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 87 JAPANSURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 88 JAPANLIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 89 JAPANNEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 90 JAPANORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 91 JAPANPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 92 JAPANNEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 93 JAPAN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 94 INDIANEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 95 INDIANEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 96 INDIANEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 97 INDIANEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 98 INDIADIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 99 INDIAIMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 100 INDIATREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 101 INDIASOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 102 INDIATARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 103 INDIARADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 104 INDIASURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 105 INDIALIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 106 INDIANEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 107 INDIAORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 108 INDIAPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 109 INDIANEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 110 INDIA NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 111 AUSTRALIANEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 112 AUSTRALIANEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 113 AUSTRALIANEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 114 AUSTRALIANEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 115 AUSTRALIA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 116 AUSTRALIA IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 117 AUSTRALIA TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 118 AUSTRALIA SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 119 AUSTRALIA TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 120 AUSTRALIA RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 121 AUSTRALIA SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 122 AUSTRALIA LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 123 AUSTRALIAEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 124 AUSTRALIAORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 125 AUSTRALIAPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 126 AUSTRALIAEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 127 AUSTRALIA NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 128 MALAYSIANEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 129 MALAYSIANEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 130 MALAYSIANEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 131 MALAYSIANEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 132 MALAYSIA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 133 MALAYSIA IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 134 MALAYSIA TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 135 MALAYSIA SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 136 MALAYSIA TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 137 MALAYSIA RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 138 MALAYSIA SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 139 MALAYSIA LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 140 MALAYSIAEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 141 MALAYSIAORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 142 MALAYSIAPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 143 MALAYSIAEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 144 MALAYSIA NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 145 INDONESIANEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 146 INDONESIANEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 147 INDONESIANEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 148 INDONESIANEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 149 INDONESIA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 150 INDONESIA IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 151 INDONESIA TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 152 INDONESIA SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 153 INDONESIA TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 154 INDONESIA RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 155 INDONESIA SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 156 INDONESIA LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 157 INDONESIAEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 158 INDONESIAORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 159 INDONESIAPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 160 INDONESIAEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 161 INDONESIA NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 162 SOUTH KOREANEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 163 SOUTH KOREANEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 164 SOUTH KOREANEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 165 SOUTH KOREANEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 166 SOUTH KOREA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 167 SOUTH KOREA IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 168 SOUTH KOREA TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 169 SOUTH KOREA SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 170 SOUTH KOREA TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 171 SOUTH KOREA RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 172 SOUTH KOREA SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 173 SOUTH KOREA LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 174 SOUTH KOREAEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 175 SOUTH KOREAORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 176 SOUTH KOREAPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 177 SOUTH KOREAEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 178 SOUTH KOREA NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 179 SINGAPORENEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 180 SINGAPORENEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 181 SINGAPORENEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 182 SINGAPORENEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 183 SINGAPORE DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 184 SINGAPORE IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 185 SINGAPORE TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 186 SINGAPORE SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 187 SINGAPORE TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 188 SINGAPORE RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 189 SINGAPORE SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 190 SINGAPORE LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 191 SINGAPOREEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 192 SINGAPOREORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 193 SINGAPOREPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 194 SINGAPOREEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 195 SINGAPORE NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 196 PHILIPPINESSNEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 197 PHILIPPINESSNEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 198 PHILIPPINESSNEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 199 PHILIPPINESSNEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 200 PHILIPPINESS DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 201 PHILIPPINESS IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 202 PHILIPPINESS TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 203 PHILIPPINESS SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 204 PHILIPPINESS TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 205 PHILIPPINESS RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 206 PHILIPPINESS SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 207 PHILIPPINESS LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 208 PHILIPPINESSEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 209 PHILIPPINESSORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 210 PHILIPPINESSPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 211 PHILIPPINESSEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 212 PHILIPPINESS NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 213 THAILAND NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 214 THAILANDNEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 215 THAILANDNEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 216 THAILANDNEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 217 THAILAND DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 218 THAILAND IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 219 THAILAND TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 220 THAILAND SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 221 THAILAND TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 222 THAILAND RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 223 THAILAND SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 224 THAILAND LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 225 THAILANDEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 226 THAILANDORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 227 THAILANDPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 228 THAILANDEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 229 THAILAND NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 230 VIETNAM NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 231 VIETNAMNEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 232 VIETNAMNEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 233 VIETNAMNEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 234 VIETNAM DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 235 VIETNAM IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 236 VIETNAM TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 237 VIETNAM SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 238 VIETNAM TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 239 VIETNAM RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 240 VIETNAM SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 241 VIETNAM LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 242 VIETNAMEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 243 VIETNAMORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 244 VIETNAMPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 245 VIETNAMEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 246 VIETNAM NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 247 REST OF ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
Lista de Figura
FIGURE 1 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: ASIA-PACIFIC VS REGIONAL ANALYSIS
FIGURE 5 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: SEGMENTATION
FIGURE 11 INCREASED AWARENESS OF NEUROENDOCRINE TUMORS CASES IS EXPECTED TO DRIVE THE ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 NON-FUNTIONAL NET SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET IN 2021 & 2028
FIGURE 13 FIVE YEAR SURVIVAL RATE OF PANCREATIC NEUROENDOCRINE TUMOR BETWEEN 2010- 2016
FIGURE 14 INCIDENCE OF NEO-ENDOCRINE NEOPLASM IN CHINA, EUROPE AND U.S.
FIGURE 15 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY CLASSIFICATION, 2020
FIGURE 16 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2020-2028 (USD MILLION)
FIGURE 17 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY CLASSIFICATION, CAGR (2021-2028)
FIGURE 18 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY CLASSIFICATION, LIFELINE CURVE
FIGURE 19 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY SITE, 2020
FIGURE 20 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY SITE, 2020-2028 (USD MILLION)
FIGURE 21 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY SITE, CAGR (2021-2028)
FIGURE 22 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY SITE, LIFELINE CURVE
FIGURE 23 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY GRADE, 2020
FIGURE 24 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2020-2028 (USD MILLION)
FIGURE 25 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY GRADE, CAGR (2021-2028)
FIGURE 26 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY GRADE, LIFELINE CURVE
FIGURE 27 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY TYPE, 2020
FIGURE 28 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2020-2028 (USD MILLION)
FIGURE 29 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 30 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 31 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 32 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)
FIGURE 33 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 34 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY ROUTE OF ADMINSTRATION, LIFELINE CURVE
FIGURE 35 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY END USER, 2020
FIGURE 36 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY END USER, 2020-2028 (USD MILLION)
FIGURE 37 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY END USER, CAGR (2021-2028)
FIGURE 38 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY END USER, LIFELINE CURVE
FIGURE 39 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 40 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 41 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 42 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 43 ASIA PACIFIC NEUROENDOCRINE TUMORS MARKET: SNAPSHOT (2020)
FIGURE 44 ASIA PACIFIC NEUROENDOCRINE TUMORS MARKET: BY COUNTRY (2020)
FIGURE 45 ASIA PACIFIC NEUROENDOCRINE TUMORS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 46 ASIA PACIFIC NEUROENDOCRINE TUMORS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 47 ASIA PACIFIC NEUROENDOCRINE TUMORS MARKET: BY STRAINS (2021-2028)
FIGURE 48 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: COMPANY SHARE 2020 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
